Search - tctmd.com

Displaying 21 - 40 of 55

Sort: Relevancy | Date

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

FDA Approves Evinacumab for Rare Homozygous FH

Michael O'Riordan

February 11, 2021

News Daily News

FDA Approves Vericiguat for High-risk Patients With HF

Michael O'Riordan

January 20, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Daily News

FDA, EU Clear Fitbit ECG to Detect Atrial Fibrillation

Michael O'Riordan

September 15, 2020

News Daily News

European Regulators Approve First Transcatheter MV Replacement Device

Michael O'Riordan

January 30, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Sapien 3 Valve Approved in Europe for Low-Risk Patients

Michael O'Riordan

November 06, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

Advertisement

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

FDA Approves Dapagliflozin for CKD Patients

Roughly 80% of ESC Guideline Writers Have Financial COIs

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

FDA Approves Evinacumab for Rare Homozygous FH

FDA Approves Vericiguat for High-risk Patients With HF

Funding the Future: How Industry Support for CV Trials Could Evolve

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

FDA, EU Clear Fitbit ECG to Detect Atrial Fibrillation

European Regulators Approve First Transcatheter MV Replacement Device

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Sapien 3 Valve Approved in Europe for Low-Risk Patients

FDA Expands TAVR Indication to Low-Risk Patients

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content